Alchemia establishes level 1 ADR program
Friday, 20 August, 2004
Brisbane biotech Alchemia (ASX: ACL) has taken the first step towards a NASDAQ listing, announcing it will be establishing a Level One American Depositary Receipt (ADR) program in coming months.
Managing director Dr Tracie Ramsdale said a NASDAQ listing was a natural extension of the company’s increasing focus on the United States, which was the primary market for its future products.
Earlier this month, Alchemia completed the scale-up of the manufacturing process for its synthetic heparin, which it is developing with partners Dow Chemical and American Pharmaceutical Partners.
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
